	US 11,840,571 B2
	Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4
Leslie S. Johnson, Darnestown, MD (US); Gurunadh Reddy Chichili, Germantown, MD (US); Kalpana Shah, Boyds, MD (US); Ross La Motte-Mohs, Boyds, MD (US); Paul A. Moore, North Potomac, MD (US); Ezio Bonvini, Potomac, MD (US); and Scott Koenig, Rockville, MD (US)
Assigned to MACROGENICS, INC., Rockville, MD (US)
Filed by MACROGENICS, INC., Rockville, MD (US)
Filed on Jan. 13, 2021, as Appl. No. 17/148,309.
Application 17/148,309 is a division of application No. 16/060,227, granted, now 10,954,301, previously published as PCT/US2016/066060, filed on Dec. 12, 2016.
Claims priority of provisional application 62/266,944, filed on Dec. 14, 2015.
Prior Publication US 2021/0130470 A1, May 6, 2021
Int. Cl. C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/46 (2006.01); C07K 16/44 (2006.01); A61K 39/395 (2006.01); A61P 31/00 (2006.01); A61P 35/00 (2006.01); A61K 38/00 (2006.01)

CPC C07K 16/2827 (2013.01) [A61K 39/395 (2013.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/30 (2013.01); C07K 16/44 (2013.01); C07K 16/46 (2013.01); C07K 16/468 (2013.01); A61K 38/00 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/64 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/01 (2013.01)]

20 Claims

1. A method for treating a disease or condition associated with a suppressed immune system, comprising administering to a subject in need thereof a composition comprising a bispecific molecule in an amount effective to treat the disease or condition, wherein the bispecific molecule comprises two polypeptide chains each comprising the polypeptide of SEQ ID NO:99 and two polypeptide chains each comprising the polypeptide of SEQ ID NO:100.